Meeting NewsVideo

VIDEO: Sparsentan shows nephroprotective potential for treatment of primary focal segmental glomerulosclerosis

SAN DIEGO — At ASN Kidney Week 2018, Howard Trachtman, MD, director of the division of pediatric nephrology at NYU Langone Health, provided an update on the DUET Trial of sparsentan, a dual angiotensin and endothelin receptor antagonist for primary focal segmental glomerulosclerosis.

“The key take-home message is that this maybe very well turn out to be a drug that will replace the angiotensin-receptor blockers alone because in a single pill you will have two complementary actions that will be synergistic to reduce proteinuria with hopefully the same safety profile that nephrologists have encountered when they use angiotensin-receptor blockers to treat proteinuric patients,” he said.

SAN DIEGO — At ASN Kidney Week 2018, Howard Trachtman, MD, director of the division of pediatric nephrology at NYU Langone Health, provided an update on the DUET Trial of sparsentan, a dual angiotensin and endothelin receptor antagonist for primary focal segmental glomerulosclerosis.

“The key take-home message is that this maybe very well turn out to be a drug that will replace the angiotensin-receptor blockers alone because in a single pill you will have two complementary actions that will be synergistic to reduce proteinuria with hopefully the same safety profile that nephrologists have encountered when they use angiotensin-receptor blockers to treat proteinuric patients,” he said.

    See more from American Society of Nephrology Annual Meeting